Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

14
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
14
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

425
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
425
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

744
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of a Digital Screening and Navigation Model in Addressing Unmet Social Needs among Parents and Caregivers in Priority Population Groups: A Randomised Controlled Trial.

International journal of integrated care·2026
Same author

Response to "Between pregnancies: An educational window in women with epilepsy".

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Perspectives of hepatitis B treatment and vaccinations within the community in Nepal: Insights from healthcare workers.

Infection, disease & health·2026
Same author

The Impact of Remoteness on the Outcomes of Children With Prenatal Drug Exposure: A Population-Based Cohort Study.

Journal of paediatrics and child health·2026
Same author

The outcomes of consecutive pregnancies in Australian women with epilepsy.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Codesign and knowledge translation of the Strength-based, Tiered, Accessible Resources and Supports (STARS) for Kids study to identify and support child development, parental mentalwell-being and family psychosocial needs: a mixed-methods research protocol.

BMJ paediatrics open·2026

Related Experiment Video

Updated: Apr 24, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

Multiple sclerosis disease modifying medicine utilisation in Australia.

Samantha Hollingworth1, Kimitra Walker2, Andrew Page3

  • 1School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba, QLD 4102, Australia.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|September 8, 2014
PubMed
Summary

Disease modifying medicine (DMM) use for relapsing remitting multiple sclerosis (RRMS) in Australia significantly increased from 1996 to 2013. Trends varied by state, with newer oral medications contributing to substantial growth.

Keywords:
FingolimodGlatiramer acetateInterferonMultiple sclerosisNatalizumabPrescribingUtilisation

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

15.9K

Related Experiment Videos

Last Updated: Apr 24, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.0K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

15.9K

Area of Science:

  • Neurology
  • Pharmacology
  • Public Health

Background:

  • Relapsing remitting multiple sclerosis (RRMS) management has evolved with new disease-modifying medicines (DMMs).
  • Understanding DMM utilization trends is crucial for healthcare planning in Australia.

Purpose of the Study:

  • To analyze the trends in DMM utilization for RRMS in Australia between 1996 and 2013.
  • To examine geographical variations in DMM use across Australian states and territories.

Main Methods:

  • Utilized prescription data from Medicare Australia.
  • Calculated defined daily doses (DDD)/1000 population/day.
  • Analyzed trends by administrative area (state/territory).

Main Results:

  • Overall RRMS DMM use increased from 0.024 to 0.68 DDD/1000 population/day (1996-2013).
  • Interferon beta agents were initially dominant, followed by glatiramer acetate, natalizumab, and fingolimod.
  • Fingolimod's introduction in 2011 significantly contributed to overall use growth.
  • Higher DMM utilization was observed in southern states compared to northern states.

Conclusions:

  • RRMS DMM use in Australia has shown progressive growth, influenced by increased confidence in treatment benefits, improved patient survival, and enhanced MS diagnosis via MRI.
  • Geographical variations in DMM preference exist across Australian states and territories.
  • The advent of oral DMMs like fingolimod has likely encouraged treatment initiation among patients previously hesitant towards injectable therapies.